Lipid nanoparticles have become the workhorse of mRNA vaccines, ferrying genetic cargo into cells so the immune system can learn to recognize a threat. But most LNPs don’t travel where vaccine developers would ideally want them to go. Instead of homing to immune tissues, they tend to accumulate in the liver—a biological detour that can limit efficacy and contribute to side effects. A team at the U...